Studies on new ophthalmic neuroprotective medicinal products (Q3789772): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the infer coords bot - inferring coordinates from location) |
(Changed an Item: Adding English translations) |
||||||||||||||
Property / summary | |||||||||||||||
The knowledge accumulated by UAB Profarma to extend the lifespan of pharmaceutical proteins can be used to prolong the lifespan of various pharmaceutical proteins. During the R & D project, it is planned to develop additional growth factors modified by Promer technology and to carry out the necessary studies. (English) | |||||||||||||||
Property / summary: The knowledge accumulated by UAB Profarma to extend the lifespan of pharmaceutical proteins can be used to prolong the lifespan of various pharmaceutical proteins. During the R & D project, it is planned to develop additional growth factors modified by Promer technology and to carry out the necessary studies. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / summary: The knowledge accumulated by UAB Profarma to extend the lifespan of pharmaceutical proteins can be used to prolong the lifespan of various pharmaceutical proteins. During the R & D project, it is planned to develop additional growth factors modified by Promer technology and to carry out the necessary studies. (English) / qualifier | |||||||||||||||
point in time: 1 February 2022
|
Revision as of 14:19, 1 February 2022
Project Q3789772 in Lithuania
Language | Label | Description | Also known as |
---|---|---|---|
English | Studies on new ophthalmic neuroprotective medicinal products |
Project Q3789772 in Lithuania |
Statements
1,263,174.93 Euro
0 references
2,027,680.13 Euro
0 references
62.3 percent
0 references
3 April 2018
0 references
31 March 2022
0 references
Uždaroji akcinė bendrovė "Profarma"
0 references
02241
0 references
UAB „Profarma“ sukauptos farmacinių baltymų gyvavimo laiko prailginimo žinios gali būti naudojamos prailginant įvairių farmacinių baltymų gyvavimo laiką. MTEP projekto metu planuojama papildomai sukurti ProMer technologija modifikuotus augimo faktorius ir atlikti reikalingus tyrimus. (Lithuanian)
0 references
The knowledge accumulated by UAB Profarma to extend the lifespan of pharmaceutical proteins can be used to prolong the lifespan of various pharmaceutical proteins. During the R & D project, it is planned to develop additional growth factors modified by Promer technology and to carry out the necessary studies. (English)
1 February 2022
0 references
V. A. Graičiūno g. 6, Vilnius
0 references
Identifiers
J05-LVPA-K-03-0073
0 references